|
Name |
Guignardone G
|
Molecular Formula | C16H22O4 | |
IUPAC Name* |
(1R,3aR,5S,7S,9aS)-5,7-dihydroxy-3a-methyl-1-prop-1-en-2-yl-1,2,3,5,6,7,9,9a-octahydrocyclopenta[b]chromen-8-one
|
|
SMILES |
CC(=C)[C@@H]1CC[C@@]2([C@H]1CC3=C(O2)[C@H](C[C@@H](C3=O)O)O)C
|
|
InChI |
InChI=1S/C16H22O4/c1-8(2)9-4-5-16(3)11(9)6-10-14(19)12(17)7-13(18)15(10)20-16/h9,11-13,17-18H,1,4-7H2,2-3H3/t9-,11-,12-,13-,16+/m0/s1
|
|
InChIKey |
XXEZBUQSFPDVPL-BYIGHTSFSA-N
|
|
Synonyms |
Guignardone G
|
|
CAS | NA | |
PubChem CID | 139583629 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 278.34 | ALogp: | 1.5 |
HBD: | 2 | HBA: | 4 |
Rotatable Bonds: | 1 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 66.8 | Aromatic Rings: | 3 |
Heavy Atoms: | 20 | QED Weighted: | 0.722 |
Caco-2 Permeability: | -4.741 | MDCK Permeability: | 0.00001760 |
Pgp-inhibitor: | 0.001 | Pgp-substrate: | 0.114 |
Human Intestinal Absorption (HIA): | 0.089 | 20% Bioavailability (F20%): | 0.76 |
30% Bioavailability (F30%): | 0.004 |
Blood-Brain-Barrier Penetration (BBB): | 0.448 | Plasma Protein Binding (PPB): | 56.21% |
Volume Distribution (VD): | 1.304 | Fu: | 53.70% |
CYP1A2-inhibitor: | 0.022 | CYP1A2-substrate: | 0.396 |
CYP2C19-inhibitor: | 0.017 | CYP2C19-substrate: | 0.783 |
CYP2C9-inhibitor: | 0.012 | CYP2C9-substrate: | 0.221 |
CYP2D6-inhibitor: | 0.003 | CYP2D6-substrate: | 0.407 |
CYP3A4-inhibitor: | 0.023 | CYP3A4-substrate: | 0.302 |
Clearance (CL): | 7.769 | Half-life (T1/2): | 0.851 |
hERG Blockers: | 0.014 | Human Hepatotoxicity (H-HT): | 0.297 |
Drug-inuced Liver Injury (DILI): | 0.58 | AMES Toxicity: | 0.027 |
Rat Oral Acute Toxicity: | 0.706 | Maximum Recommended Daily Dose: | 0.064 |
Skin Sensitization: | 0.105 | Carcinogencity: | 0.343 |
Eye Corrosion: | 0.07 | Eye Irritation: | 0.29 |
Respiratory Toxicity: | 0.595 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC003339 | 0.762 | D04VIS | 0.271 | ||||
ENC003343 | 0.762 | D0C7JF | 0.261 | ||||
ENC003344 | 0.638 | D0P0HT | 0.248 | ||||
ENC002719 | 0.556 | D04SFH | 0.245 | ||||
ENC002721 | 0.534 | D0W2EK | 0.244 | ||||
ENC003609 | 0.527 | D0Z1FX | 0.242 | ||||
ENC006128 | 0.518 | D0K0EK | 0.242 | ||||
ENC003338 | 0.474 | D0T7ZQ | 0.240 | ||||
ENC005804 | 0.463 | D06AEO | 0.238 | ||||
ENC006127 | 0.455 | D0V9DZ | 0.233 |